All Online

1 - 12 of 24 results

Refine

Active filters

Diabetes
0.25 CME CREDIT

Join us as we discuss key points from the 2019 update to the American Diabetes Association and the European Association for the Study of Diabetes consensus report. This update is now reflected in the American Diabetes Association's Standards of Medical Care—2020.


0.25 CME CREDIT

The incidence and prevalence of prediabetes and Type II Diabetes Mellitus in adolescents and young adults has increased over the past decade. A recent cross-sectional study of 12 years of NHANES data suggests that this population has an associated increased cardiometabolic risk. Listen as our team discusses these findings and some prevention strategies to help improve health outcomes.


0.25 CME CREDIT

In this episode we discuss how periodontal disease worsens A1C and other clinical outcomes in T2DM.


0.25 CME CREDIT

When patients with T2DM have difficulty controlling their glucose with standard approaches, or are newly diagnosed but severely hyperglycemic, insulin is commonly used to help control their metabolism. Using long acting, once a day agents is a standard of care but in the last 15 years, the costs of insulin has skyrocketed. During this episode we will review a study examining the effects of using Neutral Protamine Hagedorn Insulin (NPH) rather than once a day insulin on A1c control and risk for hypoglycemia and discuss their findings, which suggest NPH can be used with equivalent glycemic control and with no additional risk.


0.58 CME CREDIT

During this session (part 3 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for SGLT2 inhibitors and use a patient case to discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


1 CME CREDIT

Diabetic kidney disease is expected to surpass all other diabetes-related complications in morbidity and mortality. In this session, faculty will review current data on the renoprotective properties of SGLT2 inhibitors and explain the guideline recommendations for their use in patients with type 2 diabetes and kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/4/2019, and they are subject to change as new information is published.


0.75 CME CREDIT

In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).


1 CME CREDIT

Combining Oral Diabetes Therapies: How, When, Who, and Why?

1.00 CME/MOC
1.00 AANP | 0.40 Pharmacology

Individualized care is crucial to successful type 2 diabetes (T2DM) management. The emergence of newer oral therapies that not only help to improve glycemic control but also reduce cardiovascular and other risks has dramatically changed the landscape of diabetes care. Understanding when and how to intensify treatment with this expanded toolbox is challenging for clinicians. By reviewing the latest guidelines and clinical data, participants will receive practical strategies to maximize and combine oral therapies, increase adherence, and individualize care in the treatment of diabetes.


0.52 CME CREDIT

1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.


0.75 CME CREDIT

Two leading experts in type 2 diabetes management will review the benefits and limitations of GLP-1 receptor agonists, including a new oral agent in this class, by providing expert syntheses of clinical trial data and demonstrating how to turn this information into useful, actionable guidance for routine patient care.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.